NCT00040547已完成1 期

Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors

Merck Sharp & Dohme LLC0 个研究点目标入组 29 人开始时间: 2001年6月最近更新: 2015年2月18日

研究概览

简要总结

The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) when given in combination with intravenous docetaxel in cancer patients with advanced solid tumors.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

结局指标

主要结局

ECG

Adverse Events

Laboratory Tests

次要结局

Physical Exam
Pharmacokinetics
Tumor Response

研究者

发起方

Merck Sharp & Dohme LLC

申办方类型

Industry

责任方

Sponsor

相似试验

终止

1 期

Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)Neoplasms

NCT00040534Merck Sharp & Dohme LLC22

已完成

1 期

Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)Myelodysplastic SyndromesLeukemia, Myeloid, ChronicBlast CrisisLeukemia, LymphocyticLeukemia

NCT00034684Merck Sharp & Dohme LLC132

Unknown

1 期

Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)Cancer

NCT00006199National Center for Research Resources (NCRR)

终止

2 期

Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)Carcinoma, Squamous CellHead and Neck Neoplasms

NCT00073450Merck Sharp & Dohme LLC15

已完成

2 期

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's DiseaseMild Cognitive ImpairmentAlzheimer's Disease

NCT01661673FORUM Pharmaceuticals Inc52